Haleos Labs vs Vertex Pharmaceuticals: Fair Value & Quality
Both stocks run through our valuation models. Here is how Haleos Labs (HALEOSLABS) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 17, 2026.
As of Aug 17, 2026, Fair Value Calculator sees Haleos Labs as the less overvalued of the two: Haleos Labs trades at ₹1,484 versus a fair value of ₹969 (-35%), while Vertex Pharmaceuticals trades at $506 versus $279 (-45%).
Haleos Labs
HALEOSLABS.NSE · INR · Healthcare
-35%
upside to fair value
overvalued
Price₹1,484
Fair Value₹969
Quality42/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-45%
upside to fair value
overvalued
Price$506
Fair Value$279
Quality79/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Haleos LabsVertex Pharmaceuticals
Valuation
25.9×P/E (TTM)28.8×
1.48×P/S (TTM)10.06×
2.31×P/B6.59×
12.1×EV/EBITDA23.8×
—PEG1.72×
0.1%Dividend yield0.1%
₹1.50Dividend per share—
Profitability
5%Net margin36%
0%Operating margin38%
8%Return on equity24%
4%Return on assets12%
Growth
-16%Revenue growth (YoY)8%
2.2%Avg. growth/yr (3Y)10.6%
4.7%Avg. growth/yr (5Y)14.2%
Balance & size
0.23×Debt / equity0.03×
$52MMarket cap$123B
expensiveGrowth qualityhealthy
Vertex Pharmaceuticals leads: 4 to 9 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Haleos Labsof which business quality 44 · market factors 63Vertex Pharmaceuticalsof which business quality 77 · market factors 70
ProfitabilityMargins and returns on capital today
35
72
Quality GrowthAre margins and returns improving?
17
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
50
58
Low VolatilityCalm price path (market factor)
70
86
MomentumPrice trend over the last 3–12 months (market factor)
59
58
52W MomentumDistance to the 52-week high (market factor)
63
74
Net IssuanceBuybacks instead of dilution
82
82
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Haleos Labs
Earnings-Based₹680
Dividend Discount₹18.11
Multiples₹1,179
Asset-Based₹473
Economic Profit₹608
Growth Earnings₹969
12 of 14 models see the stock below the current price.
Vertex Pharmaceuticals
DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692
19 of 26 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Haleos Labs
Bear ₹678Fair Value ₹969Bull ₹1,260
₹1,484 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$506 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Haleos Labs · Healthcare
Quality score42 · below median
Fair value upside-35% · below median
Vertex Pharmaceuticals · Health Care
Quality score79 · Top 25%
Fair value upside-45% · below median
Bottom line
As of Aug 17, 2026, Fair Value Calculator sees Haleos Labs as the less overvalued of the two: Haleos Labs trades at ₹1,484 versus a fair value of ₹969 (-35%), while Vertex Pharmaceuticals trades at $506 versus $279 (-45%).
Vertex Pharmaceuticals has the higher quality score (79/100).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
